Description: Genotype-specific treatment strategies for cardiovascular disease are in trials and development. Traditional animal models of disease lack a human genetic background, partially limiting the applicability of the models to study genetic testing and disease-specific therapeutics. The FDA Reauthorization Act 2.0 allows for the use of non-animal testing to assess the safety and efficacy of therapeutics, but there is little guidance on how to actualize this in practice. Non-animal preclinical models, including patient-specific induced pluripotent stem cells, are likely to become increasingly more important. This session aims to capture this rapidly advancing field, including the spectrum of model systems, the cardiovascular disease types that can be captured, the therapeutic strategies that can be assessed and the evolving landscape of regulation. In particular, this session explores the application of model systems towards assessing therapeutics.

Moderator(s):
Jordan E Ezekian (UT Southwestern Medical Center)
Matthew G Nayor (Boston Unviersity Medical Center)

Panelist(s):
Mauro Giacca (Kings College London)
Sharon Ann George (University of Pittsburgh)
Joseph C Wu (STANFORD UNIV SCH OF MEDICINE)